Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Meta Expands AI Training With Employee Activity Tracking Tools 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
NEW YORK, March 17, 2017 -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 27th Annual Oppenheimer Healthcare Conference, being held at The Westin Grand Central Hotel in New York City. The presentation is scheduled to take place on Tuesday, March 21, 2017 at 3:20pm ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX - G
CONTACT: Jenna Bosco Vice President- Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: [email protected]
